Logos Global Management LP Jounce Therapeutics, Inc. Transaction History

Logos Global Management LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.8 - $7.67 $3.92 Million - $10.7 Million	-1,400,000 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$6.01 - $8.54 $300,500 - $426,999	50,000 Added 3.7%	1,400,000 $9.51 Million
Q4 2021 Feb 14, 2022	SELL	$7.11 - $9.64 $4.62 Million - $6.27 Million	-650,000 Reduced 32.5%	1,350,000 $11.3 Million
Q3 2021 Nov 15, 2021	BUY	$5.04 - $8.73 $10.1 Million - $17.5 Million	2,000,000 New	2,000,000 $14.9 Million

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Logos Global Management LP, based on Form 13F filings with the SEC.

Stay updated on Logos Global Management LP with notifications on news.